Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Gastroenterology · MUTYH-Associated Polyposis

What Is the Genetic Difference Between MAP and FAP?

At a Glance

MAP and FAP are different inherited polyposis syndromes: MAP results from disease-causing changes in both copies of the MUTYH gene and often causes fewer, later polyps, while FAP usually involves one APC change and causes many earlier polyps. Both require lifelong monitoring.

Learning that you have MUTYH-Associated Polyposis (MAP) instead of Familial Adenomatous Polyposis (FAP) is an important distinction that directly impacts your medical care and family planning. Being reclassified can be confusing, but the core difference is genetic: FAP is caused by a single mutation in the APC gene, while MAP requires two mutations (pathogenic variants) in the MUTYH gene [1] [2]. Clinically, MAP generally causes fewer polyps, often develops later in life, and may allow for careful removal of polyps via colonoscopy rather than immediately requiring surgery [1] [3] [4]. However, “fewer polyps” does not mean “no risk,” and strict monitoring remains essential [5] [6].

Quick Comparison: MAP vs. FAP

Feature FAP (Classic) MAP
Gene Involved APC [1] MUTYH [1]
Inheritance Autosomal Dominant (1 altered copy needed) Autosomal Recessive (2 altered copies needed)
Typical Polyp Count Hundreds to thousands [1] Often 10 to 100, but can be fewer or more [3]
Bowel Management Preventative surgery is almost always needed [7] Often managed with regular colonoscopies [4]
Extracolonic Risks High risk for desmoid tumors, thyroid issues [8] Lower risk for these specific FAP complications [9]

How the Genetics and Inheritance Differ

The most fundamental difference between MAP and FAP is how they are passed down through families:

  • FAP is autosomal dominant: It only takes one mutated APC gene from one parent to cause the condition. Each child of someone with FAP has a 50% chance of inheriting it.
  • MAP is autosomal recessive: You must inherit two mutated copies of the MUTYH gene (one from each parent) to have MAP [2].

If you have MAP, you have two mutated MUTYH copies. Here is what that means for your family [1]:

  • For your children: You will pass one mutated copy to every child. If your partner does not have any MUTYH mutations, all your children will be “carriers” (having only one mutation) but will not have MAP. If your partner is a carrier, each pregnancy has a 50% chance of the child having MAP and a 50% chance of being a carrier. If your partner also has MAP, all children will have MAP.
  • For your siblings: Because your parents were likely both carriers, each of your full siblings has a 25% chance of having MAP, a 50% chance of being a carrier, and a 25% chance of being neither.

It is crucial to confirm your genetic report shows you have two pathogenic variants (biallelic) in the MUTYH gene. Having only one variant makes you a carrier, which does not cause MAP [10] [2]. First-degree relatives should be referred to a genetic counselor for targeted testing [11].

Differences in Polyps and Risk

While classic FAP is known for causing massive numbers of polyps beginning in childhood, MAP typically presents a milder picture:

  • Number of polyps: People with MAP often develop between 10 and 100 polyps [3]. However, this is just an average. Colorectal cancer can sometimes develop with fewer than 10 polyps present [12].
  • Age of onset: MAP tends to develop later in life (e.g., around age 50), whereas classic FAP is often diagnosed in childhood or early adolescence [7] [3].

Important: These are averages, not strict rules. MAP can present earlier, and a low polyp count does not guarantee safety [12]. Surveillance should be guided by your specific genetics and specialist plan, not by waiting to reach a certain age or waiting for symptoms to appear.

Care, Colonoscopies, and Surgery Timing

The practical difference in treating MAP versus FAP lies in how the colon is managed:

  • Endoscopic Surveillance: This means using a camera test (colonoscopy) to find and remove polyps before they become cancer. Because MAP generally produces fewer polyps, many patients can be safely managed this way for years, provided the exams are high-quality and all risky lesions can be completely removed [4].
  • When Surgery is Considered: In classic FAP, risk-reducing surgery is generally planned once the polyp burden becomes unmanageable or high-risk features appear, rather than at a fixed age [7] [13]. For MAP, surgery is discussed if polyps become too numerous to safely remove via colonoscopy, if they grow too large, if high-grade dysplasia (advanced pre-cancer) or cancer is found, or if reliable surveillance is not possible [4] [12] [14].
  • Surgical Options: If surgery is needed, the procedure will be tailored to you. For MAP, a rectum-preserving surgery (like a subtotal colectomy with an ileorectal anastomosis) is often possible, where the colon is removed but the rectum is kept [7] [15]. This is different from FAP, which sometimes requires removing both the colon and rectum and creating a surgical pouch (ileal pouch).

Monitoring Other Parts of the Body

Both MAP and FAP require screening outside of the colon, particularly in the stomach and duodenum (the first part of the small intestine), but there are differences:

  • Upper GI Tract: Duodenal polyps develop less frequently and at a later age in MAP than in FAP [8]. Your doctor will use an upper endoscopy and the Spigelman score—a system that grades your duodenal polyps based on their number, size, and microscopic features—to decide how often you need this test [16] [17]. Depending on your score, endoscopies might happen anywhere from every 6 months to every 5 years, completely customized to your findings.
  • Post-Surgery Surveillance: If you have had any colon surgery, the remaining tissue (whether a retained rectum or a surgical pouch) requires lifelong endoscopic surveillance [4]. This is not always strictly yearly; the interval depends on your specific anatomy, previous polyp burden, and your doctor’s recommendations [4] [18].
  • Other FAP Risks: FAP comes with risks for desmoid tumors (non-cancerous but aggressive growths) and thyroid issues, which are rarely reported in MAP [9]. Do not assume all FAP screening protocols apply to you; ask your specialist what extracolonic screening you actually need for MAP.

Symptom Safety Net and Next Steps

Even if you are on a strict surveillance schedule, you should never wait for your next appointment if you develop concerning symptoms. Contact your care team promptly if you experience:

  • Rectal bleeding or blood in your stool
  • Unexplained iron-deficiency anemia or weight loss
  • Persistent changes in bowel habits (like new diarrhea or constipation)
  • Severe or ongoing abdominal pain

Your Next Steps:

  • Get your genetic report: Confirm with your doctor or genetic counselor that you have two pathogenic MUTYH variants.
  • Plan family testing: Work with a genetic counselor to arrange targeted testing for your partner and relatives.
  • Confirm surveillance dates: Know exactly when your next high-quality colonoscopy and upper endoscopy are scheduled.
  • Review your plan: Discuss with your specialist which FAP-specific screenings you can stop, and what your personalized MAP surveillance plan should be.

Common questions in this guide

How are MAP and FAP different genetically?
MAP occurs when both copies of the MUTYH gene have disease-causing changes, so a person usually inherits one from each parent. FAP usually results from one disease-causing change in APC, and each child of an affected parent has a 50% chance of inheriting it.
Does having one MUTYH mutation mean I have MAP?
No. MAP requires disease-causing changes in both copies of MUTYH. Someone with one changed copy is a carrier and generally does not have MAP, although genetic counseling may be recommended for family planning and testing relatives.
Does MAP cause fewer polyps than FAP?
Often, yes. MAP commonly causes about 10 to 100 polyps and tends to appear later, while classic FAP can cause hundreds to thousands of polyps and is often diagnosed in childhood or early adolescence. These are averages: colorectal cancer can occur with fewer than 10 polyps, so a low count does not remove the need for surveillance.
Will I need surgery if I have MAP?
No. Many people with MAP can have polyps found and removed during regular, high-quality colonoscopies. Surgery may be recommended when polyps are too numerous or large to remove safely, advanced precancerous changes or cancer are found, or reliable surveillance is not possible.
What screening is needed outside the colon for MAP or FAP?
Both conditions require monitoring of the colon and the upper digestive tract, especially the stomach and duodenum. An upper endoscopy and the Spigelman score—which considers the number, size, and microscopic features of duodenal polyps—help determine how often testing is needed. Any remaining rectum or surgical pouch also needs lifelong endoscopic surveillance.
What does a MAP diagnosis mean for my family?
MAP is inherited differently from FAP, so family testing is important. If both parents carry a MUTYH change, each full sibling has a 25% chance of MAP, a 50% chance of being a carrier, and a 25% chance of having neither change. A person with MAP passes one changed copy to every child, but the child's risk of MAP depends on the other parent's MUTYH results.

Get notified when new evidence is published on Familial Adenomatous Polyposis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    c.1227_1228dupGG (p.Glu410Glyfs), a frequent variant in Tunisian patients with MUTYH associated polyposis.

    Kdissa A, Brusgaard K, Ksiaa M, et al.

    Cancer genetics 2020; (240()):45-53 doi:10.1016/j.cancergen.2019.10.007.

    PMID: 31739127
  2. 2

    Association of functional variants and protein-to-protein physical interactions of human MutY homolog linked with familial adenomatous polyposis and colorectal cancer syndrome.

    Abduljaleel Z, Athar M, Al-Allaf FA, et al.

    Non-coding RNA research 2019; (4(4)):155-173 doi:10.1016/j.ncrna.2019.11.005.

    PMID: 32072083
  3. 3

    Attenuated adenomatous polyposis of the large bowel: Present and future.

    Roncucci L, Pedroni M, Mariani F

    World journal of gastroenterology 2017; (23(23)):4135-4139 doi:10.3748/wjg.v23.i23.4135.

    PMID: 28694653
  4. 4

    Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights.

    Aelvoet AS, Buttitta F, Ricciardiello L, Dekker E

    Best practice & research. Clinical gastroenterology 2022; (58-59()):101793 doi:10.1016/j.bpg.2022.101793.

    PMID: 35988966
  5. 5

    The genetic puzzle of FAP: exploring novel diagnostic approaches for APC/MUTYH-negative case.

    Grot N, Kazimierczyk M, Szuman M, et al.

    Hereditary cancer in clinical practice 2025; (23(1)):25 doi:10.1186/s13053-025-00318-7.

    PMID: 41204315
  6. 6

    MUTYH-associated tumor syndrome: The other face of MAP.

    Magrin L, Fanale D, Brando C, et al.

    Oncogene 2022; (41(18)):2531-2539 doi:10.1038/s41388-022-02304-y.

    PMID: 35422474
  7. 7

    Colorectal family polyadenomatous diseases. What management in 2020?

    Menahem B, Alves A, Regimbeau JM, Sabbagh C

    Journal of visceral surgery 2020; (157(2)):127-135 doi:10.1016/j.jviscsurg.2019.12.003.

    PMID: 32113818
  8. 8

    Frequency and Features of Duodenal Adenomas in Patients With MUTYH-Associated Polyposis.

    Walton SJ, Kallenberg FG, Clark SK, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2016; (14(7)):986-92.

    PMID: 26905905
  9. 9

    Phenotype Correlations With Pathogenic DNA Variants in the MUTYH Gene: A Review of Over 2000 Cases.

    Thet M, Plazzer JP, Capella G, et al.

    Human mutation 2024; (2024()):8520275 doi:10.1155/2024/8520275.

    PMID: 40225933
  10. 10

    First report of MUTYH-associated polyposis with c.1353_1355del and c.452A>G mutations in Tolima Grande region from Colombia: a case report.

    Bohórquez-Lozano M, Suarez-Olaya J, Rubio-Vargas AC, et al.

    Frontiers in oncology 2026; (16()):1873371 doi:10.3389/fonc.2026.1873371.

    PMID: 42676843
  11. 11

    ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

    Syngal S, Brand RE, Church JM, et al.

    The American journal of gastroenterology 2015; (110(2)):223-62; quiz 263 doi:10.1038/ajg.2014.435.

    PMID: 25645574
  12. 12

    MUTYH-associated polyposis - colorectal phenotype and management.

    Patel R, McGinty P, Cuthill V, et al.

    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 2020; (22(10)):1271-1278 doi:10.1111/codi.15078.

    PMID: 32307808
  13. 13

    The importance of genetics for timing and extent of surgery in inherited colorectal cancer syndromes.

    Aoun RJN, Kalady MF

    Surgical oncology 2022; (43()):101765 doi:10.1016/j.suronc.2022.101765.

    PMID: 35643746
  14. 14

    Updated European guidelines for clinical management of familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), gastric adenocarcinoma, proximal polyposis of the stomach (GAPPS) and other rare adenomatous polyposis syndromes: a joint EHTG-ESCP revision.

    Zaffaroni G, Mannucci A, Koskenvuo L, et al.

    The British journal of surgery 2024; (111(5)) doi:10.1093/bjs/znae070.

    PMID: 38722804
  15. 15

    Multistage Management of Splenic Flexure Adenocarcinoma in Suspected MUTYH-Associated Polyposis: A Case Report.

    Costanzi A, Tapia Gomez H, Schievano G, et al.

    Annali italiani di chirurgia 2026; (97(4)):625-630 doi:10.62713/aic.4277.

    PMID: 41987631
  16. 16

    Endoscopic management of duodenal adenomatosis in familial adenomatous polyposis-A case-based review.

    Soons E, Bisseling TM, van Kouwen MCA, et al.

    United European gastroenterology journal 2021; (9(4)):461-468 doi:10.1002/ueg2.12071.

    PMID: 34529357
  17. 17

    The impact of chromoendoscopy for surveillance of the duodenum in patients with MUTYH-associated polyposis and familial adenomatous polyposis.

    Hurley JJ, Thomas LE, Walton SJ, et al.

    Gastrointestinal endoscopy 2018; (88(4)):665-673 doi:10.1016/j.gie.2018.04.2347.

    PMID: 29702101
  18. 18

    Adenomatous Polyposis Syndromes: Diagnosis and Management.

    Mitchem JB, Hall JF

    Clinics in colon and rectal surgery 2016; (29(4)):321-329 doi:10.1055/s-0036-1584089.

    PMID: 31777463

This comparison of MAP and FAP is for education only and does not replace medical advice. A genetic counselor, gastroenterologist, or colorectal specialist can interpret your results and tailor your surveillance plan.